| Literature DB >> 33885003 |
Ridwan Alam1, Matthew J Rabinowitz1, Taylor P Kohn1, Vanessa N Peña1, James L Liu1, Yasin Bhanji1, Amin S Herati1.
Abstract
Adoption of the prostatic urethral lift (PUL) as a treatment for benign prostatic hyperplasia highlights the importance of training residents with novel technology without compromising patient care. This study examines the effect of resident involvement during PUL on patient and procedural outcomes. Retrospective chart review was conducted on all consecutive PUL cases performed by a single academic urologist between October 2017 and November 2019. Trainees in post-graduate year (PGY) 1-3 are considered junior residents, while those in PGY 4-6 are senior residents. The International Prostate Symptom Score (IPSS) and quality of life (QOL) scores were used to measure outcomes. Simple and mixed-effects linear regression models were used to compare differences. There were 110 patients with a median age of 66.4 years. Residents were involved in 73 cases (66.4%), and senior residents were involved in 31 of those cases. Resident involvement was not associated with adverse perioperative outcomes with respect to the number of implants fired, the percentage of implants successfully placed, or the postoperative catheterization rate. After adjustment for confounding factors, junior residents were associated with significantly longer case length compared to the attending alone (+12.6 min, P = 0.003) but senior residents were not (+2.4 min, P = 0.59). IPSS and QOL scores were not significantly affected by resident involvement (P = 0.12 and P = 0.21, respectively). The presence of surgeons-in-training, particularly those in the early stages, prolongs PUL case length but does not appear to have an adverse impact on patient outcomes.Entities:
Keywords: internship and residency; operative time; prostatic hyperplasia; prostheses and implants; quality of life
Mesh:
Year: 2021 PMID: 33885003 PMCID: PMC8577266 DOI: 10.4103/aja.aja_21_21
Source DB: PubMed Journal: Asian J Androl ISSN: 1008-682X Impact factor: 3.285
Baseline demographic factors of all patients, including stratification by resident involvement
|
|
|
|
|
|
|---|---|---|---|---|
| Age (year), median (IQR) | 66.4 (60.4–73.7) | 65.7 (59.0–71.9) | 68.8 (64.3–76.3) | 0.06 |
| African-American, | 19 (17.2) | 13 (17.8) | 6 (16.2) | 0.83 |
| Comorbidities, | ||||
| Chronic kidney disease | 14 (12.7) | 12 (16.4) | 2 (5.4) | 0.10 |
| Chronic obstructive pulmonary disease | 10 (9.1) | 9 (12.3) | 1 (2.7) | 0.10 |
| Diabetes mellitus | 19 (17.2) | 15 (20.5) | 4 (10.8) | 0.20 |
| Hypertension | 58 (52.7) | 41 (56.2) | 17 (45.9) | 0.31 |
| Myocardial infarction | 3 (2.7) | 2 (2.7) | 1 (2.7) | 0.99 |
| Stroke | 5 (4.5) | 4 (5.5) | 1 (2.7) | 0.51 |
| On medical therapy, | 102 (92.7) | 65 (89.0) | 37 (100.0) | 0.04 |
| Obstructive median lobe present, | 23 (20.9) | 17 (23.3) | 6 (16.2) | 0.39 |
| Intravesical protrusion distance (cm), median (IQR) | 0.8 (0.6–1.1) | 0.9 (0.6–1.5) | 0.7 (0.5–0.9) | 0.27 |
| Preoperative IPSS, median (IQR) | 20 (13–24) | 21 (13–25) | 20 (15–23) | 0.76 |
| Preoperative QOL, median (IQR) | 4 (3–5) | 4 (3–5) | 4 (3–5) | 0.98 |
IPSS: International Prostate Symptom Score; IQR: interquartile range; QOL: quality of life
Perioperative outcomes stratified by level of resident experience
|
|
|
|
|
|---|---|---|---|
| Total implants fired, | 5.4 (1.7) | 5.4 (1.4) | 0.99 |
| Percentage of implants successfully placed, percentage (s.d.) | 97.1 (8.3) | 98.7 (4.2) | 0.31 |
| Required postoperative catheter, | 7 (22.6) | 13 (31.0) | 0.43 |
s.d.: standard deviation
Univariable and multivariable linear regression analyses of patient and case characteristics on the outcome of operative time
|
|
|
| ||
|---|---|---|---|---|
|
|
| |||
|
|
|
|
| |
| Experience | ||||
| Attending | Reference | Reference | ||
| Senior resident | 3.3 (−5.2–11.7) | 0.44 | 2.4 (−6.4–11.0) | 0.59 |
| Junior resident | 11.4 (3.6–19.3) | 0.005 | 12.6 (4.2–20.9) | 0.003 |
| Age (per year) | −0.5 (−0.8–−0.2) | 0.003 | −0.4 (−0.7–0) | 0.03 |
| African-American | 2.4 (−6.7–11.5) | 0.60 | 1.9 (−7.0–10.7) | 0.67 |
| Comorbidities (per comorbidity) | −2.0 (−5.5–1.5) | 0.26 | −2.1 (−5.7–1.5) | 0.25 |
| On medical therapy | 7.7 (−5.4–20.8) | 0.25 | 9.0 (−4.1–22.2) | 0.18 |
| Obstructive median lobe present | 6.4 (−2.0–14.7) | 0.13 | 2.1 (−6.4–10.5) | 0.62 |
The coefficient represents the additional operative time